(Q34207580)

31 July 2017

1 reference

title

Structured treatment interruptions to control HIV-1 and limit drug exposure (English)

1 reference

31 July 2017

Montaner LJ

1

1 reference

31 July 2017

publication date

1 February 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

92-96

1 reference

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Resistance, fitness, adherence, and potency: mapping the paths to virologic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

What is missing in immunology to understand immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Infection-immunity in experimental salmonellosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

The CD4(+) T cell response to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Antiretroviral resistance during successful therapy of HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Is interruption of HIV therapy always harmful?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2800%2901809-3

7 January 2021

10.1016/S1471-4906(00)01809-3

Identifiers

DOI

1 reference

31 July 2017

1 reference